Catalog No.: PC-21570Not For Human Use, Lab Use Only.
Birelentinib (DZD8586) is an oral, non-covalent, BBB penetrant LYN and BTK dual inhibitor, overcomes resistance mutations to the approved covalent and non-covalent BTK inhibitors.
Birelentinib (DZD8586) is an oral, non-covalent, BBB penetrant LYN and BTK dual inhibitor, overcomes resistance mutations to the approved covalent and non-covalent BTK inhibitors.
DZD8586 exhibits good selectivity against multiple kinases was assessed at Eurofins panel with purified enzymes.
DZD8586 demonstrateS concentration dependent anti-proliferative effects, with similar GI50s among cells carrying different BTK mutations.
DZD8586 exhibitS potent cell growth inhibition and induced cell death in a variety of cell lines in a panel of DLBCL cell lines.
DZD8586 (50 mg/kg) exhibitS profound tumor growth inhibition in a dose-dependent manner, and induces tumor regression in both subcutaneous and CNS tumor models.
